A case for botulinum toxin-a in idiopathic bladder overactivity

Current Urology Reports

Volumn 5, Issue 6, 2004, Pages 432-436

  Smith, Christopher P ^b   Somogyi, George T ^b   Chancellor, Michael B ^b   Appell, Rodney A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

Botulinum Toxin; Botulinum Toxin Type; Detrusor Overactivity; Neurogenic Detrusor Overactivity; Spinal Cord Injured Patient

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

BLADDER; DRUG EFFECT; HUMAN; INJECTION; PATHOPHYSIOLOGY; REVIEW; URINE INCONTINENCE;

BOTULINUM TOXIN TYPE A; HUMANS; INJECTIONS; NEUROMUSCULAR AGENTS; URINARY BLADDER; URINARY INCONTINENCE;

EID: 16644399478     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-004-0066-y     Document Type: Article

References (39)

1. van Ermengem E: Ueber einen neuen anaeroben Bacillus and seine Beziehungen zum Botulisms. Ztsch Hyg Infekt 1897, 26:1. DOI: 10.1007/BF02220526
2. Petit H, Wiart E, Gaujard E, et al.: Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord 1998, 36:91–94. DOI: 10.1038/sj.sc.3100517
3. Dykstra DD, Sidi A: Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double blind study. Arch Phys Med Rehabil 1990, 71:24–26.
4. Dykstra DD, Sidi AA, Scott AB, et al.: Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988, 139:919–922. First documented use of BTX within the lower urinary tract.
5. Chancellor MB, de Groat WC: Intravesical capsaicin and resiniferatoxin: spicing up the ways to treat the overactive bladder. J Urol 1999, 162:3–11. DOI: 10.1097/00005392-199907000-00002
6. Stohrer M, Schurch B, Kramer G, et al.: Botulinum toxin-A toxin in the treatment of detrusor hyperreflexia in spinal cord injured patients: a new alternative to medical and surgical procedures? Neurourol Urodyn 1999, 18:401. DOI: 10.1002/(SICI)1520-6777(1999)18:2<139::AID-NAU9>3.0.CO;2-U
7. Schurch B, Stohrer M, Kramer G, et al.: Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results. J Urol 2000, 164:692–697. First manuscript describing the use of bladder injections of BTX to treat DH in spinal cord injured patients. DOI: 10.1016/S0022-5347(05)67283-7
8. Del Popolo G: Botulinum-A toxin in the treatment of detrusor hyperreflexia [Abstract]. Neurourol Urodyn 2001, 20:522–524.
9. Heckmann M, Ceballos-Baumann AO, Plewig G, Hyperhidrosis Study Group: Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 2001, 344:488–493. DOI: 10.1056/NEJM200102153440704
10. Porta M, Gamba M, Bertacchi G, Vaj P: Treatment of sialorrhoea with ultrasound-guided botulinum toxin type A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry 2001, 70:538–540. DOI: 10.1136/jnnp.70.4.538
11. Von Lindern JJ, Niederhagen B, Berge S, et al.: Frey syndrome: treatment with type A botulinum toxin. Cancer 2000, 89:1659–1663. DOI: 10.1002/1097-0142(20001015)89:8<1659::AID-CNCR2>3.0.CO;2-M
12. Schurch B, Stöhrer M, Kramer G, et al.: Botulinum toxin-A to treat detrusor hyperreflexia in spinal cord injured patients [Abstract]. Neurourol Urodyn 2001, 20:521–522.
13. Reitz A, Stohrer M, Kramer G, et al.: European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004, 45:510–515. DOI: 10.1016/j.eururo.2003.12.004
14. Hernandez RD, Hurwitz RS, Foote JE, et al.: Nonsurgical management of threatened upper urinary tracts and incontinence in children with myelomeningocele. J Urol 1994, 152:1582–1585.
15. Skobejko-Wlodarska L, Strulak K, Nachulewicz P, Szymkiewicz C: Bladder autoaugmentation in myelodysplastic children. Br J Urol 1998, 81(suppl 3):114–116.
16. Schulte-Baukloh H, Michael T, Sturzebecher B, Knispel HH: Botulinum A-toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 2003, 44:139–143. DOI: 10.1016/S0302-2838(03)00136-2
17. Riccabona M, Koen M, Schindler M, et al.: Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 2004, 171:845–848. DOI: 10.1097/01.ju.0000108892.35041.2d
18. Giannantoni A, Di Stasi SM, Stephen RL, et al.: Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective, randomized study. J Urol 2004, 172:240–243. Prospective, randomized study comparing the effects of BTX versus RTX in patients with neurogenic bladder dysfunction. DOI: 10.1097/01.ju.0000132152.53532.5d
19. Grosse JO, Kramer G, Lochner-Ernst D, Stohrer M: Outcome of repeat detrusor injections of botulinum A toxin (BTX-A) for severe neurogenic detrusor overactivity and incontinence. J Urol 2003, 169(suppl):373. DOI: 10.1016/S0022-5347(05)64130-4
20. Radziszewski P, Dobronski P, Borkowski A: Treatment of the non-neurogenic storage and voiding disorders with the chemical denervation caused by botulinum toxin type A: a pilot study [Abstract]. Neurourol Urodyn 2001, 20:410–412.
21. Zermann DH, Ishigooka M, Schubert J, Schmidt RA: Trigonum and bladder base injection of botulinum toxin A (BTX) in patients with severe urgency-frequency-syndrome refractory to conservative medical treatment and electrical stimulation [Abstract]. Neurourol Urodyn 2001, 20:412–413.
22. Loch A, Loch T, Osterhage J, et al.: Botulinum-A toxin detrusor injections in the treatment of non-neurologic and neurologic cases of urge incontinence. J Urol 2003, 169(suppl):124.
23. Chancellor MB, O’Leary M, Erickson J, et al.: Successful use of bladder botulinum toxin injection to treat refractory overactive bladder. J Urol 2003, 169(suppl):351. DOI: 10.1016/S0022-5347(03)80072-1
24. Rapp DE, Lucioni A, Katz EE, et al.: Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 2004, 63:1071–1075. First published manuscript describing the beneficial effects of BTX in patients with refractory OAB. DOI: 10.1016/j.urology.2004.01.041
25. Dykstra D, Enriquez A, Valley M: Treatment of overactive bladder with botulinum toxin type B: a pilot study. Int Urogynecol J 2003, 14:424–426. DOI: 10.1007/s00192-003-1099-3
26. Smith CP, Franks ME, McNeil BK, et al.: Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 2003, 169:1896–1900. DOI: 10.1097/01.ju.0000049202.56189.54
27. Somogyi GT, Zernova GV, Yoshiyama M, et al.: Frequency dependence of muscarinic facilitation of transmitter release in urinary bladder strips from neurally intact or chronic spinal cord transected rats. Br J Pharmacol 1998, 125:241–246. DOI: 10.1038/sj.bjp.0702041
28. Hawthorn MH, Chapple CR, Cock M, Chess-Williams R: Urothelium-derived inhibitory factor(s) influence detrusor muscle contractility in vitro. Br J Pharmacol 2000, 129:416–419. DOI: 10.1038/sj.bjp.0703068
29. Wakabayashi Y, Kojima Y, Makiura Y, et al.: Free terminal fibers of autonomic nerves in the mucosa of the cat urinary bladder. In Recent Advances in Cellular and Molecular Biology, vol 3. Edited by Wegmann RJ, Wegmann MA. Leuven, Belgium: Peeters Press; 1992:109–117.
30. Wakabayashi Y, Kojima Y, Makiura Y, et al.: Acetylcholinesterase positive axons in the mucosa of urinary bladder of adult cats: retrograde tracing and degeneration studies. Histol Histopathol 1995, 10:523–530.
31. Andersson KE, Yoshida M: Antimuscarinics and the overactive detrusor: Which is the main mechanism of action? Eur Urol 2003, 43:1–5. DOI: 10.1016/S0302-2838(02)00540-7
32. Smith CP, Boone TB, de Groat WC, et al.: Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res Bull 2003, 61:165–171. DOI: 10.1016/S0361-9230(03)00114-X
33. O’Reilly BA, Kosaka AH, Knight GF, et al.: P2X receptors and their role in female idiopathic detrusor instability. J Urol 2002, 167:157–164. DOI: 10.1016/S0022-5347(05)65403-1
34. Cui M, Khanijou S, Rubino J, Aoki KR: Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004, 107:125–133. DOI: 10.1016/j.pain.2003.10.008
35. Vemulakonda VM, Somogyi GT, Kiss S, et al.: Inhibitory effect of intravesically applied botulinum toxin A in chronic bladder inflammation. J Urol 2004, in press.
36. Smith CP, Chancellor MB: Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol 2004, 171:2128–2137. Comprehensive review on the mechanisms of action of BTX, techniques of injection, and laboratory and clinical results regarding its use within the lower urinary tract. DOI: 10.1097/01.ju.0000127725.48479.89
37. Khera M, Somogyi GT, Kiss S, et al.: Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 2004, 45:987–993. Basic research indicating, at least in the laboratory setting, that BTX may have inhibitory effects on bladder sensory pathways in addition to its well-documented effects on efferent nerves. DOI: 10.1016/j.neuint.2004.06.001
38. Pistolesi D, Selli C, Rossi B, Stampacchia G: Botulinum toxin type B for type A resistant bladder spasticity. J Urol 2004, 171:802–803. DOI: 10.1097/01.ju.0000108844.10235.f1
39. Reitz A, Schurch B: Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity. J Urol 2004, 171:804–805. DOI: 10.1097/01.ju.0000108407.53880.6a